CompletedPhase 3NCT01926236
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
Studying Carcinoma of the ampulla of Vater
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Christie NHS Foundation Trust
- Principal Investigator
- Juan Valle, ProfThe Christie NHS Foundation Trust
- Intervention
- Active Symptom Control(other)
- Enrollment
- 162 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2019
Study locations (17)
- Queen Elizabeth Hospital, Birmingham, United Kingdom
- Bristol Haematology & Oncology Centre, Bristol, United Kingdom
- North Cumbria University Hospitals, Carlisle, United Kingdom
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
- Castle Hill Hospital, Hull, United Kingdom
- St James' Hospital, Leeds, United Kingdom
- Clatterbridge Cancer Centre, Liverpool, United Kingdom
- Guy's and St Thomas' Hospital, London, United Kingdom
- Hammersmith Hospital, London, United Kingdom
- Royal Free Hospital, London, United Kingdom
- University College London, London, United Kingdom
- Maidstone Hospital, Maidstone, United Kingdom
- The Christie NHS Foundation Trust, Manchester, United Kingdom
- Nottingham City Hospital, Nottingham, United Kingdom
- Churchill Hospital, Oxford, United Kingdom
- +2 more locations on ClinicalTrials.gov
Collaborators
Cancer Research UK
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01926236 on ClinicalTrials.govOther trials for Carcinoma of the ampulla of Vater
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07282912Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) LevelsYale University
- RECRUITINGPHASE3NCT07081360Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary CancerMinia University
- RECRUITINGNANCT06801899ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary CancerInsel Gruppe AG, University Hospital Bern
- RECRUITINGNANCT05780684Individualized Dose Escalation of 5-FU for Gastrointestinal CancerDartmouth-Hitchcock Medical Center
- RECRUITINGNANCT06068023The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.Fondazione Poliambulanza Istituto Ospedaliero
- ENROLLING BY INVITATIONNANCT06076252Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary CarcinomaAffiliated Hospital of Guangdong Medical University
- RECRUITINGNANCT05497531Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic CancersUniversity of California, Irvine
- RECRUITINGPHASE1, PHASE2NCT05116072Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative FistulaUniversity Hospital, Lille